During the past decade, convincing evidence has accumulated that conquering heart disease is not simply a matter of driving serum cholesterol down. In fact, one-half of the people who have a heart attack have normal cholesterol and now low cholesterol is being associated with a significant risk of early cognitive decline. New information is available. Clinicians are no longer limited to using antiquated measures of cholesterol, blood pressure, and blood sugars as the primary markers of increased risk for cardiometabolic disorders: advanced lipid assays, markers of oxidative stress, inflammation, hormones, and body composition are all providing new opportunities for safer and more effective early interventions to prevent and reverse cardiometabolic disease.
IFM’S CARDIOMETABOLIC ADVANCED PRACTICE MODULE
The module will help clinicians understand the physiology underlying cardiometabolic syndrome and cardiovascular disease, new approaches to effective assessments and treatments, and how to integrate these lifesaving tools into practice.